Chapter 1. RECOMBINANT VACCINES MARKET – Scope & Methodology

1.1. Market Segmentation

1.2. Assumptions

1.3. Research Methodology

1.4. Primary Sources

1.5. Secondary Sources

Chapter 2. RECOMBINANT VACCINES MARKET – Executive Summary

2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)

2.2. Key Trends & Insights

2.3. COVID-19 Impact Analysis

      2.3.1. Impact during 2023 – 2030

      2.3.2. Impact on Supply – Demand

Chapter 3. RECOMBINANT VACCINES MARKET – Competition Scenario

3.1. Market Share Analysis

3.2. Product Benchmarking

3.3. Competitive Strategy & Development Scenario

3.4. Competitive Pricing Analysis

3.5. Supplier - Distributor Analysis

Chapter 4. RECOMBINANT VACCINES MARKET - Entry Scenario

4.1. Case Studies – Start-up/Thriving Companies

4.2. Regulatory Scenario - By Region

4.3 Customer Analysis

4.4. Porter's Five Force Model

       4.4.1. Bargaining Power of Suppliers

       4.4.2. Bargaining Powers of Customers

       4.4.3. Threat of New Entrants

       4.4.4. Rivalry among Existing Players

       4.4.5. Threat of Substitutes

Chapter 5. RECOMBINANT VACCINES MARKET - Landscape

5.1. Value Chain Analysis – Key Stakeholders Impact Analysis

5.2. Market Drivers

5.3. Market Restraints/Challenges

5.4. Market Opportunities

Chapter 6. RECOMBINANT VACCINES MARKET – by Indication

6.1. Human Papillomavirus

6.2. Meningococcal

6.3. Others

Chapter 7. RECOMBINANT VACCINES MARKET – By End User

7.1. Pediatric

7.2. Adults

Chapter 8. RECOMBINANT VACCINES MARKET – By Distribution Channel

8.1. Hospitals

8.1.1. Type

8.1.1.1. Private

8.1.1.2. Public

8.2. Vaccination Centers

Chapter 9. RECOMBINANT VACCINES MARKET – By Region

9.1. North America

9.2. Europe

9.3.The Asia Pacific

9.4.Latin America

9.5. Middle-East and Africa

Chapter 10. RECOMBINANT VACCINES MARKET– Company Profiles – (Overview, Product Portfolio, Financials, Developments)

10.1. Company 1

10.2. Company 2

10.3. Company 3

10.4. Company 4

10.5. Company 5

10.6. Company 6

10.7. Company 7

10.8. Company 8

10.9. Company 9

10.10. Company 10